Thomson Reuters Launches New Developments to Support Synthetic Chemists

    PHILADELPHIA and LONDON, Aug. 13 /CNW/ -- Thomson Reuters today announced
the newest release of Prous Science Integrity  developed in response to demand
from synthetic chemists in pharmaceutical and fine chemical companies.

    The redesigned Organic Synthesis Knowledge Area within Prous Science
Integrity allows researchers to directly retrieve intermediates and reagents,
as well as synthesis schemes, to pinpoint key characteristics of synthesis
route components in seconds.  New visualizations and filtering methods plus
incorporation of the latest industry standard chemical taxonomony (InChIs)
enable new research approaches that save time and provide insights. All these
new capabilities can be applied to the foundation of 19,000 schemes of
synthesis and 85,000+ structure-searchable intermediates that make Prous
Science Integrity a powerful resource to synthetic chemists in the
pharmaceuticals and fine chemicals industries.

    Pharmaceutical synthetic chemists will value this improved support to
easily identify competitor activity, evaluate newly designed synthetic routes
and locate suppliers of selected intermediates, while chemists at fine
chemicals companies will be able to identify what new drugs are in development
and at what phase, giving them the opportunity to promote their existing
chemicals, develop new intermediates or highlight alternative steps in a
synthesis scheme.

    "Prous Science Integrity is being developed to encompass the new paradigm
of translational research," said Josep Prous, Jr., Ph.D., Vice President and
Chief Scientific Officer at Thomson Reuters. "The features found in this most
recent version support the quality data and innovative functionality that
customers have come to expect from Thomson Reuters."

    Thomson Reuters will be attending the 238th American Chemical Society's
National Meeting and Exposition, August 16-20, 2009 in Washington, DC and
ChemOutsourcing, September 14-16, 2009 in Long Branch, NJ.  Researchers are
encouraged to come and receive a demonstration of the latest changes to Prous
Science Integrity.

    The upgrade is the first of several planned phases over the next year
that will increase the depth and breadth of information and add new features,
while continuing to provide the highest quality content.

    Prous Science Integrity seamlessly integrates biological, chemical and
pharmacological information on more than 300,000 compounds with demonstrated
biological activity, plus tens of thousands of synthesis intermediates and
over 125,000 patent family records. Updated daily, this unique database is
designed to support the drug discovery and development activities for
thousands of pharmacologists and medicinal chemists as well as other
scientific researchers.  Find out more about Prous Science Integrity here.

    About Thomson Reuters
    Thomson Reuters is the world's leading source of intelligent information
for businesses and professionals.  We combine industry expertise with
innovative technology to deliver critical information to leading decision
makers in the financial, legal, tax and accounting, scientific, healthcare and
media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs more than 50,000 people in 93 countries. For more
information, go to


For further information:

For further information: Sue Besaw of Healthcare & Science for Thomson
Reuters, +1-215-823-1840, Web Site:

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890